COMPANY

Nuvectis Pharma

HQ: Fort Lee, NJ source · nuvectis.com ↗ · Mid-Atlantic

Location: Fort Lee, NJ · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: NSCLC (Non-small Cell Lung Cancer) Renal Cancer Mesothelioma Non-Small Cell Squamous Lung Cancer Non-small Cell Lung Adenocarcinoma ALK Positive ALK Positive Non-small Cell Lung Cancer NSCLC ALK+ Non-Small-Cell Lung Carcinoma Ovarian Cancer Ovarian Clear Cell Carcinoma Ovarian Clear Cell Tumor Ovarian Clear Cell Adenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Endometrioid Tumor ARID1A Gene Mutation EGFR Mutation Positive Non-small Cell Lung Cancer NXP900 NXP800

$15.5MRaised (2 yrs)4Trials (company is sponsor)

Timeline

Aug 17, 2026 Trial start Phase 1: Study of NXP900 With Lorlatinib in ALK+ Lung Cancer source ↗
Jun 23, 2026 Partnership Partnership / licensing announced Jun 23, 2026. Source: SEC filing. source ↗
Dec 18, 2025 Trial start Phase 1: Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer source ↗
Feb 7, 2025 Raise Follow-on offering: $15.5M (total, as published), announced Feb 7, 2025. Source: company release on GlobeNewswire. source ↗
Oct 26, 2023 Trial start 1: A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers source ↗
Dec 31, 2021 Trial start 1: A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Phase 1 · Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer · NCT07315113
2027-03 (ESTIMATED) · 1 · A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers · NCT05873686
2027-08 (ESTIMATED) · Phase 1 · Study of NXP900 With Lorlatinib in ALK+ Lung Cancer · NCT07784959

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $15.5M. Last 2 years.

Feb 7, 2025 Follow-on offering: $15.5M (total, as published), announced Feb 7, 2025. Source: company release on GlobeNewswire. source ↗
Jun 23, 2026 Partnership / licensing announced Jun 23, 2026. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT05873686	A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers	1	Active, not recruiting	Oct 26, 2023	2027-03 (estimated)
NCT07784959	Study of NXP900 With Lorlatinib in ALK+ Lung Cancer	Phase 1	Recruiting	Aug 17, 2026	2027-08 (estimated)
NCT05226507	A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer	1	Terminated	Dec 31, 2021	Jan 1, 2025 (actual)
NCT07315113	Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer	Phase 1	Recruiting	Dec 18, 2025	2026-12 (estimated)